Omidria qualifies for separate payment in ASCs under the CMS policy for non-opioid pain management surgical drugs when used in the ASC setting, according to an Omeros press release.
“I think this is great news as uptake should increase Omidria usage,” Mitchell A. Jackson, MD, told Healio/OSN.
Omidria (phenylephrine 1% and ketorolac 0.3% intraocular solution), approved for use in adults and children, prevents pupil constriction during surgery and reduces postoperative ocular pain.
“It’s a victory for everybody. Patients get better and safer surgery with less pain and less
Uncategorized